PT969873E - Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso - Google Patents

Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso

Info

Publication number
PT969873E
PT969873E PT98913748T PT98913748T PT969873E PT 969873 E PT969873 E PT 969873E PT 98913748 T PT98913748 T PT 98913748T PT 98913748 T PT98913748 T PT 98913748T PT 969873 E PT969873 E PT 969873E
Authority
PT
Portugal
Prior art keywords
same
multiple antigen
carbon hydrate
vaccine coating
antigen glycopeptide
Prior art date
Application number
PT98913748T
Other languages
English (en)
Inventor
Bay Sylvie
Cantacuzene Daniele
Leclerc Claude
Lo-Man Richard
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of PT969873E publication Critical patent/PT969873E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645Dendrimers; Multiple antigen peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Carbon And Carbon Compounds (AREA)
PT98913748T 1997-03-27 1998-03-27 Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso PT969873E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4172697P 1997-03-27 1997-03-27

Publications (1)

Publication Number Publication Date
PT969873E true PT969873E (pt) 2006-09-29

Family

ID=21918009

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98913748T PT969873E (pt) 1997-03-27 1998-03-27 Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso

Country Status (10)

Country Link
US (1) US7696326B2 (pt)
EP (1) EP0969873B1 (pt)
AT (1) ATE328611T1 (pt)
AU (1) AU6832398A (pt)
CA (1) CA2285018C (pt)
DE (1) DE69834808T2 (pt)
DK (1) DK0969873T3 (pt)
ES (1) ES2265162T3 (pt)
PT (1) PT969873E (pt)
WO (1) WO1998043677A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP2002536008A (ja) * 1999-02-11 2002-10-29 ジェンザイム・コーポレーション 抗原ペプチドコンカテマー
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
KR20050099536A (ko) 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
US9079765B2 (en) 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2007079448A2 (en) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
ES2366552T3 (es) 2006-01-13 2011-10-21 Institut Pasteur Síntesis enzimática a gran escala de glicoconjugados de mucina y sus aplicaciones en inmunología.
EP2076557A4 (en) 2006-08-11 2012-08-29 Starpharma Pty Ltd POLYLYSINE DENDRIMER CONTRAST AGENT
CN101516969B (zh) * 2006-08-11 2013-07-03 星药股份有限公司 靶向的聚赖氨酸树状聚体治疗剂改性的大分子2
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
BRPI1016133A2 (pt) * 2009-04-01 2016-04-19 Univ Miami vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula.
EP2500033A1 (en) * 2011-03-17 2012-09-19 Institut Pasteur Method for preparing muliple antigen glycopeptide carbohydrate conjugates
EA201590427A1 (ru) * 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017101786A1 (zh) * 2015-12-14 2017-06-22 韩苏 一种多肽化合物及其制备方法与应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1991017773A2 (de) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh Neue protein-polykation-konjugate
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof

Also Published As

Publication number Publication date
CA2285018C (en) 2011-01-04
US7696326B2 (en) 2010-04-13
CA2285018A1 (en) 1998-10-08
DE69834808T2 (de) 2007-06-06
WO1998043677A1 (en) 1998-10-08
US20070098730A1 (en) 2007-05-03
DE69834808D1 (de) 2006-07-20
ATE328611T1 (de) 2006-06-15
EP0969873B1 (en) 2006-06-07
AU6832398A (en) 1998-10-22
ES2265162T3 (es) 2007-02-01
DK0969873T3 (da) 2006-10-09
EP0969873A1 (en) 2000-01-12

Similar Documents

Publication Publication Date Title
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DE69222956D1 (de) Kleinste erkennungseinheit eines pem-mucin-"tandem repeat"-spezifischen monoklonalen antikoerpers
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
NZ506553A (en) Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
ATE444081T1 (de) Proteine-abgabe durch polare epithelzellen schichte
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ES2122921A1 (es) Proteinas recombinantes de fusion del virus del sindrome reproductivo y respiratorio porcino (prsv) y su empleo en diagnostico.
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
FR2718849B1 (fr) Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
ES2092960A1 (es) Gen de la proteina 1 de union a transferrina (tbp1) de actinobacillus pleuropneumoniae, utilizacion de esta en la preparacion de productos para la vacunacion contra la pleuroneumonia y en reactivos de diagnostico.
EP1388543A3 (en) Antibodies against phosphorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)